IntReALL Phase II/III Clinical Trial - Evaluation of new therapies to improve survival of children with relapsed acute lymphoblastic leukaemia

IntReALL II/III 期临床试验 - 评估新疗法可提高复发性急性淋巴细胞白血病儿童的生存率

• 批准号: nhmrc : 1024232
• 负责人: A/Pr Rosemary Sutton
• 金额: $ 111.36万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/intreall-phase-iiiii-lymphoblastic-leukaemia/110331
• 关键词: IntReALL; Phase; II; III; Clinical

Children who relapse with childhood leukaemia have only a 50% chance of being alive after 5 years. We will participate in a new international trial involving most European and all Australian and New Zealand childhood oncology centres, to test the effectiveness of promising new treatments and to perform biological studies which should enable doctors in future to pick the best treatment for each of these patients.

儿童白血病复发的儿童在5年后只有50%的机会存活。我们将参加一项新的国际试验，涉及大多数欧洲和所有澳大利亚和新西兰的儿童肿瘤中心，以测试有希望的新治疗方法的有效性，并进行生物学研究，使医生将来能够为每个患者选择最佳治疗方法。